#Levi & Korsinsky #Aardvark Therapeutics #NASDAQ AARD

Aardvark Therapeutics Faces a Class Action Lawsuit

Aardvark Therapeutics, Inc. (NASDAQ: AARD) has recently found itself embroiled in a significant securities class action lawsuit that raises serious concerns regarding the safety claims made about its product ARD-101. Investors who purchased shares between February 13, 2025, and May 14, 2026, including those involved in its initial public offering (IPO) in February 2025, are being alerted to this legal proceeding by Levi & Korsinsky, LLP.

Background on the Class Action

The crux of the lawsuit centers on allegations that key executives at Aardvark—including the Chief Executive Officer Tien-Li Lee, Chief Financial Officer Nelson Sun, and former Chief Operating Officer Bryan Jones—were responsible for misrepresentations and misleading statements about the safety of ARD-101. These claims became particularly pressing when the company faced a pause in its Phase 3 HERO trial and subsequently received an FDA clinical hold on the drug's usage, which triggered a sharp decline of approximately 71.4% in its stock price from an initial offering of $16.00 per share down to $4.57.

Allegations of Misleading Information

The lawsuit asserts that these executives possessed critical information regarding the safety profile of ARD-101 that was not communicated clearly to the public. According to the legal filings, the executives had access to internal assessments indicating that ARD-101 might not be as safe as represented, specifically claiming it was